

Meike Vogler

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8450014/meike-vogler-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

1,527
citations

18
h-index

39
g-index

39
ext. papers

1,758
ext. citations

6.9
avg, IF

4.71
L-index

#	Paper	IF	Citations
37	Pediatric multicellular tumor spheroid models illustrate a therapeutic potential by combining BH3 mimetics with Natural Killer (NK) cell-based immunotherapy.. <i>Cell Death Discovery</i> , 2022 , 8, 11	6.9	2
36	It's time to die: BH3 mimetics in solid tumors. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021 , 1868, 118987	4.9	11
35	Unleashing the power of NK cells in anticancer immunotherapy. <i>Journal of Molecular Medicine</i> , 2021 , 1	5.5	2
34	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 173	22.4	26
33	A direct comparison of selective BH3-mimetics reveals BCL-X, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. <i>British Journal of Cancer</i> , 2020 , 122, 1544-1551	8.7	9
32	Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X and MCL-1 leads to rapid induction of intrinsic apoptosis. <i>Cancer Letters</i> , 2020 , 482, 19-32	9.9	20
31	Specific interactions of BCL-2 family proteins mediate sensitivity to BH3-mimetics in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020 , 105, 2150-2163	6.6	9
30	Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. <i>International Journal of Cancer</i> , 2020 , 147, 1485-1498	7.5	4
29	Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways. <i>Cell Death and Differentiation</i> , 2020 , 27, 1878-1895	12.7	5
28	DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition. <i>Biomolecules</i> , 2020 , 10,	5.9	3
27	BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models. <i>Cell Death and Disease</i> , 2020 , 11, 769	9.8	10
26	Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. <i>Biological Chemistry</i> , 2019 , 400, 181-185	4.5	6
25	Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. <i>Cell Death and Disease</i> , 2019 , 10, 917	9.8	15
24	Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies. <i>Haematologica</i> , 2019 , 104, 1016-1025	6.6	8
23	Identification of Smac mimetics as novel substrates for p-glycoprotein. <i>Cancer Letters</i> , 2019 , 440-441, 126-134	9.9	7
22	-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3K. <i>Cancer Research</i> , 2018 , 78, 2000-2013	10.1	10
21	Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells. <i>Cancer Letters</i> , 2018 , 428, 160-172	9.9	24

20	BCL-x-selective BH3 mimetic sensitizes rhabdomyosarcoma cells to chemotherapeutics by activation of the mitochondrial pathway of apoptosis. <i>Cancer Letters</i> , 2018 , 412, 131-142	9.9	19
19	Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. <i>Cancers</i> , 2018 , 10,	6.6	16
18	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. <i>Oncotarget</i> , 2018 , 9, 20075-20088	3.3	56
17	BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis. <i>Oncogene</i> , 2018 , 37, 5325-5339	9.2	22
16	Targeting anti-apoptotic BCL2 family proteins in haematological malignancies - from pathogenesis to treatment. <i>British Journal of Haematology</i> , 2017 , 178, 364-379	4.5	53
15	Targeting BCL2-Proteins for the Treatment of Solid Tumours. <i>Advances in Medicine</i> , 2014 , 2014, 943648	2.3	62
14	ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets. <i>British Journal of Haematology</i> , 2013 , 163, 139-42	4.5	82
13	Response: BH3 mimetics modulate calcium homeostasis in platelets. <i>Blood</i> , 2012 , 119, 1321-1322	2.2	12
12	The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. <i>Biochemical and Biophysical Research Communications</i> , 2011 , 408, 344-9	3.4	15
11	BCL2/BCL-X(L) inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. <i>Blood</i> , 2011 , 117, 7145-54	2.2	140
10	Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. <i>Clinical Cancer Research</i> , 2010 , 16, 4217-25	12.9	42
9	Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. <i>Haematologica</i> , 2010 , 95, 1510-8	6.6	61
8	Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. <i>Cancer Research</i> , 2009 , 69, 2425-34	10.1	133
7	Response: Microenvironment-dependent resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 114, 2561-2562	2.2	9
6	Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. <i>Blood</i> , 2009 , 113, 1710-22	2.2	122
5	Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 4403-13	2.2	263
4	Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. <i>Cancer Research</i> , 2008 , 68, 7956-65	10.1	137
3	Small Molecule XIAP Inhibitors Cooperate with TRAIL to Trigger Apoptosis in Childhood Acute Leukemia Cells and Overcome Bcl-2-Mediated Resistance. <i>Blood</i> , 2008 , 112, 857-857	2.2	2

2	Inhibition of clonogenic tumor growth: a novel function of Smac contributing to its antitumor activity. <i>Oncogene</i> , 2005 , 24, 7190-202	9.2	38
1	Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. <i>Cancer Research</i> , 2005 , 65, 10502-13	10.1	62